Mydecine Innovations Group Inc.

Equities

MYCOF

CA62849F2008

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:48:02 2024-05-10 EDT			5-day change	1st Jan Change
0.0112 ^USD	+112.04%		0.00%	-24.83%

05-01	Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding	CI
02-23	Mydecine Innovations Closes Partial Debt Settlement	MT

Mydecine Innovations Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023

Mydecine Innovations Group Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CAD 11.57 million compared to CAD 28.9 million a year ago. Basic loss per share was CAD 1.34 compared to CAD 6.17 a year ago.

Latest news about Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding	04-30	CI
Mydecine Innovations Closes Partial Debt Settlement	02-23	MT
Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director	02-02	CI
Mydecine Innovations Group Receives Notice of Allowance from USPTO For MYCO-005 Compound	12-18	MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Mydecine Innovations Group Provided Q4 2023 Business Update	23-10-26	MT
Mydecine Innovations Group Brief: Announced Admission to Trading on AQSE Growth Market in London, UK and First Day of Dealings	23-10-10	MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary	23-07-21	CI
Mydecine Innovations Group Appoints Todd Heinzl to the Board of Directors	23-05-29	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Mydecine Innovations Group Inc. Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting Emp Analogues	23-04-24	CI
Mydecine Innovations Group Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Pangenomic Health Inc. completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).	22-12-08	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer	22-09-23	CI
Pangenomic Health Inc. signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.	22-08-31	CI
Mydecine Innovations Group Inc. Announces Board Changes	22-08-29	CI
Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs	22-08-29	CI
Mydecine Innovations Group Announces CFO Changes	22-08-19	CI
Mydecine Innovations Group Inc. Announces Board Changes	22-08-19	CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Mydecine Innovations Group Inc. announced that it has received CAD 0.245 million in funding	22-08-15	CI
Mydecine Innovations Group Inc. announced that it expects to receive CAD 0.245 million in funding	22-08-14	CI

Chart Mydecine Innovations Group Inc.

Duration

Period

More charts

Company Profile

Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Companyâs principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MYDECINE INNOVATIONS GROUP INC.	-24.83%	694K
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research